Clinical Trial

Sac-TMT Combined With Bevacizumab in TNBC With Brain Metastases

Name: Sac-TMT Combined With Bevacizumab in TNBC With Brain Metastases — clinical trial record (NCT07623577)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This is a single-arm, multi-center phase II study to evaluate the safety and efficacy Sacituzumab Tirumotecan (Sac-TMT) plus bevacizumab in triple-negative breast cancer patients with brain metastases. Twenty-four participants are planned to be enrolled. The eligible patients should have histologically or cytologically confirmed TNBC with BM.

Trial Details

NCT Number	NCT07623577
Lead Sponsor	Fudan University
Conditions	TNBC, Brain Metastasis
Enrollment	24 participants
Start Date	2026-01-01
Primary Completion	2027-01 (estimated)
Study Completion	2027-12 (estimated)
Updated on ClinicalTrials.gov	2026-06-03